IP Library › Granted Patent US 12,440,653
Granted Patent B2
US 12,440,653 · App. 18/151,574 · Granted Oct 14, 2025

Methods and apparatus to increase secretion of endogenous naturetic hormones

Inventors: Howard Levin (Teaneck, NJ); Mark Gelfand (New York, NY)
Assignee: BackBeat Medical, LLC
A61M25/10181A61M25/10A61M25/1018A61M25/10184A61M29/00A61N1/36117A61N1/3627A61N1/368A61N1/37235A61M2025/102
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,440,653
App. No.
18/151,574
Granted
Oct 14, 2025
Kind
B2
Abstract

A method and apparatus for treatment of heart failure by increasing secretion of endogenous naturetic hormones ANP and BNP such as by stimulation of the heart atria. Heart pacing is done at an atrial contraction rate that is increased and can be higher than the ventricular contraction rate. Pacing may include mechanical distension of the right atrial appendage. An implantable device is used to periodically cyclically stretch the walls of the appendage with an implanted balloon.

Claims (42)

1. A programmable implantable pacemaker connectable to at least one electrically conductive lead for connecting to a heart of a patient suffering from a condition comprising at least one of hypertension, excessive fluid retention, or excessive sodium retention,

wherein the pacemaker is programmed to:

during a first pacing period, facilitate a synchronous pace of at least one atrium and at least one ventricle of the patient's heart;

during a second pacing period, asynchronously pace the at least one atrium of the patient's heart at an atrial pacing rate and synchronously pace the at least one ventricle of the patient's heart at a ventricular pacing rate, such that the atrial pacing rate exceeds the ventricular pacing rate,

wherein during the pacing of the second pacing period, a wall of the at least one atrium is stressed beyond a natural stress condition due to the atrial pacing rate,

wherein the stressed wall secretes a hormone at an elevated secretion level above a secretion level occurring while a natural atrial rate and a natural ventricular rate are equal,

wherein the elevated secretion level of the secreted hormone achieves a beneficial therapeutic effect in the patient, and

wherein the beneficial therapeutic effect includes at least one of: limiting a degree of vasoconstriction, limiting a degree of sodium retention, increasing urine output, inhibiting a renin-angiotensin system, inhibiting endothelin secretion, inhibiting systemic and renal sympathetic activity, or counteracting effects of at least one of norepinephrine, endothelin, or angiotensin II; and

repeatedly alternate the first pacing period and the second pacing period to pace the patient's heart, wherein each alternating second pacing period has a duration of at least ten minutes.

2. The pacemaker of claim 1 , wherein during the second pacing period, electric conduction from the at least one atrium to the at least one ventricle of the patient's heart is blocked.

3. The pacemaker of claim 1 , wherein the pacemaker is programmed to receive sensor input of a sinus rhythm of the patient's heart and to selectively synchronize the ventricular pacing rate with the sinus rhythm.

4. The pacemaker of claim 1 , wherein the first pacing period is of a longer duration than the second pacing period.

5. The pacemaker of claim 1 , wherein the secreted hormone is at least one of an atrial natriuretic peptide (ANP) or a brain natriuretic peptide (BNP).

6. The pacemaker of claim 1 , wherein the beneficial therapeutic effect includes a treatment of heart failure.

7. The pacemaker of claim 1 , wherein the pacemaker is programmed to artificially induce the pacing during the first pacing period.

8. The pacemaker of claim 1 , further comprising one or more electrically conductive leads connected to the pacemaker.

9. A programmable implantable pacemaker connectable to at least one electrically conductive lead for connecting to a heart of a patient suffering from a condition comprising at least one of hypertension, excessive fluid retention, or excessive sodium retention,

wherein the pacemaker is programmed to:

during a first pacing period, facilitate a synchronous pace of at least one atrium and at least one ventricle of the patient's heart;

during a second pacing period, pace the patient's heart to cyclically stress walls of the at least one atrium of the patient's heart and restore the walls of the at least one atrium to a substantially pre-stressed condition, such that the stressed walls secrete a hormone at an elevated level above a natural secretion level occurring naturally when the patient's heart is not paced,

wherein the hormone secreted at the elevated level achieves a beneficial therapeutic effect in the patient, and

wherein the beneficial therapeutic effect includes at least one of: limiting a degree of vasoconstriction, limiting a degree of sodium retention, increasing urine output, inhibiting a renin-angiotensin system, inhibiting endothelin secretion, inhibiting systemic and renal sympathetic activity, or counteracting effects of at least one of norepinephrine, endothelin, or angiotensin II; and

repeatedly alternate the first pacing period and the second pacing period to pace the patient's heart, wherein each alternating second pacing period has a duration of at least ten minutes.

10. The pacemaker of claim 9 , wherein the pacing of the patient's heart during the second pacing period includes pacing the at least one atrium of the patient's heart at an atrial pacing rate and pacing the at least one ventricle at a ventricular pacing rate, such that the atrial pacing rate and the ventricular pacing rate are cyclically repeated to achieve the beneficial therapeutic effect.

11. The pacemaker of claim 9 , wherein the pacemaker is programmed to stress the walls of the at least one atrium by pacing the at least one atrium at an accelerated rate during the second pacing period.

12. The pacemaker of claim 9 , wherein the pacemaker is programmed to pace the at least one atrium of the patient's heart to contract atrial muscle at a cyclical rate faster than a ventricular contraction rate of the patient's heart.

13. The pacemaker of claim 9 , wherein the pacemaker is programmed to artificially induce the pacing during the first pacing period.

14. The pacemaker of claim 9 , further comprising one or more electrically conductive leads connected to the pacemaker.

15. A programmable implantable pacemaker connectable to at least one electrically conductive lead for connecting to a heart of a patient suffering from a condition comprising at least one of hypertension, excessive fluid retention, or excessive sodium retention,

wherein the pacemaker is programmed to:

during a first pacing period, facilitate a synchronous pace of at least one atrium and at least one ventricle of the patient's heart;

during a second pacing period, pace the patient's heart to achieve an atrial contraction rate faster than a ventricular contraction rate,

wherein due to the faster atrial contraction rate, at least one wall of the at least one atrium of the patient's heart is stressed due to the pacing during the second pacing period,

wherein due to the stressing of the at least one wall, a tissue in the at least one wall secretes greater amounts of a hormone as compared to a secretion amount of the hormone occurring when the pacing of the second pacing period is not applied to the patient's heart,

wherein the secretion of the greater amounts of the hormone achieves a beneficial therapeutic effect to the patient, and

wherein the beneficial therapeutic effect includes at least one of: limiting a degree of vasoconstriction, limiting a degree of sodium retention, increasing urine output, inhibiting a renin-angiotensin system, inhibiting endothelin secretion, inhibiting systemic and renal sympathetic activity, or counteracting effects of at least one of norepinephrine, endothelin, or angiotensin II; and

repeatedly alternate the first pacing period and the second pacing period to pace the patient's heart, wherein each alternating second pacing period has a duration of at least ten minutes.

16. The pacemaker of claim 15 , wherein the pacing of the patient's heart during the second pacing period includes pacing the at least one atrium at an atrial pacing rate that is faster than the ventricular contraction rate.

17. The pacemaker of claim 15 , wherein the pacing of the patient's heart during the second pacing period includes pacing a ventricle of the patient's heart at a ventricular pacing rate slower than the atrial contraction rate.

18. The pacemaker of claim 15 , wherein during the second pacing period, atrial electric impulses are blocked from reaching the at least one ventricle of the patient's heart.

19. The pacemaker of claim 15 , wherein during the second pacing period, atrial depolarization is blocked from reaching the at least one ventricle of the patient's heart and causing ventricular depolarization.

20. The pacemaker of claim 15 , wherein the pacemaker is programmed to artificially induce the pacing during the first pacing period.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2023
From: LEVIN, HOWARD; GELFAND, MARK
To: G&L CONSULTING, LLC
Reel/Frame 062312/0142 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2023
From: G&L CONSULTING, LLC
To: BACKBEAT MEDICAL, INC.
Reel/Frame 062312/0433 →
ENTITY CONVERSION Recorded Jan 9, 2023
From: BACKBEAT MEDICAL, INC.
To: BACKBEAT MEDICAL, LLC
Reel/Frame 062324/0447 →
Continuity (8)
Continuation 16453311 · Jun 26, 2019
Continuation 15613344 · Jun 5, 2017
Continuation 13960015 · Aug 6, 2013
Continuation 13426068 · Mar 21, 2012
Continuation 11276461 · Mar 1, 2006
Provisional Application 60678220 · May 6, 2005
Provisional Application 60657389 · Mar 2, 2005
Related Publication 20230233817A1 · Jul 27, 2023
References Cited (400)
US 3683934A · Bukowiecki et al. · 1972 [cited by applicant]
US 3939844A · Pequignot · 1976 [cited by applicant]
US 4712555A · Thornander et al. · 1987 [cited by applicant]
US 5154171A · Chirife · 1992 [cited by applicant]
US 5199428A · Obel et al. · 1993 [cited by applicant]
US 5213098A · Bennett et al. · 1993 [cited by applicant]
US 5601613A · Florio et al. · 1997 [cited by applicant]
US 5800334A · Wilk · 1998 [cited by applicant]
US 5928271A · Hess et al. · 1999 [cited by applicant]
US 5971911A · Wilk · 1999 [cited by applicant]
US 6045531A · Davis · 2000 [cited by applicant]
US 6157859A · Alt · 2000 [cited by applicant]
US 6241678B1 · Afremov et al. · 2001 [cited by applicant]
US 6377852B1 · Bornzin et al. · 2002 [cited by applicant]
US 6507756B1 · Heynen et al. · 2003 [cited by applicant]
US 6668195B2 · Warman et al. · 2003 [cited by applicant]
US 6701187B1 · Bornzin et al. · 2004 [cited by applicant]
US 7096064B2 · Deno et al. · 2006 [cited by applicant]
US 7155284B1 · Whitehurst et al. · 2006 [cited by applicant]
US 7184832B2 · Deno et al. · 2007 [cited by applicant]
US 7233824B2 · Kleckner et al. · 2007 [cited by applicant]
US 7286873B2 · Havel et al. · 2007 [cited by applicant]
US 7289849B2 · Baynham · 2007 [cited by applicant]
US 7363077B1 · Min et al. · 2008 [cited by applicant]
US 7580747B1 · Farazi et al. · 2009 [cited by applicant]
US 7674222B2 · Nikolic et al. · 2010 [cited by applicant]
US 7869874B2 · Levin et al. · 2011 [cited by applicant]
US 7877144B2 · Coles, Jr. et al. · 2011 [cited by applicant]
US 7908008B2 · Ben-David et al. · 2011 [cited by applicant]
US 8019416B2 · Pastore et al. · 2011 [cited by applicant]
US 8165674B2 · Levin et al. · 2012 [cited by applicant]
US 8187160B2 · Criscione et al. · 2012 [cited by applicant]
US 8224444B2 · Ben-David et al. · 2012 [cited by applicant]
US 8295928B2 · Salo et al. · 2012 [cited by applicant]
US 8340763B2 · Levin et al. · 2012 [cited by applicant]
US 8504149B2 · Libbus et al. · 2013 [cited by applicant]
US 8515536B2 · Levin et al. · 2013 [cited by applicant]
US 8521280B2 · Levin et al. · 2013 [cited by applicant]
US 8571656B2 · Stahmann et al. · 2013 [cited by applicant]
US 8632470B2 · Stahmann et al. · 2014 [cited by applicant]
US 8805494B2 · Libbus et al. · 2014 [cited by applicant]
US 9008769B2 · Mika et al. · 2015 [cited by applicant]
US 9108062B2 · Stahmann et al. · 2015 [cited by applicant]
US 9333352B2 · Mika et al. · 2016 [cited by applicant]
US 9370661B2 · Levin et al. · 2016 [cited by applicant]
US 9370662B2 · Mika et al. · 2016 [cited by applicant]
US 9427586B2 · Levin et al. · 2016 [cited by applicant]
US 9526900B2 · Mika et al. · 2016 [cited by applicant]
US 9592390B2 · Stahmann et al. · 2017 [cited by applicant]
US 9656086B2 · Mika et al. · 2017 [cited by applicant]
US 9687636B2 · Levin · 2017 [cited by examiner]
US 9731136B2 · Levin et al. · 2017 [cited by applicant]
US 9878162B2 · Mika et al. · 2018 [cited by applicant]
US 9937351B2 · Mika et al. · 2018 [cited by applicant]
US 10004905B2 · Stahmann et al. · 2018 [cited by applicant]
US 10071250B2 · Mika et al. · 2018 [cited by applicant]
US 10173067B2 · Shuros et al. · 2019 [cited by applicant]
US 10252060B2 · Levin et al. · 2019 [cited by applicant]
US 10252061B2 · Mika et al. · 2019 [cited by applicant]
US 10342982B2 · Mika et al. · 2019 [cited by applicant]
US 10369333B2 · Levin et al. · 2019 [cited by applicant]
US 10441794B2 · Mika et al. · 2019 [cited by applicant]
US 10485658B2 · Mika et al. · 2019 [cited by applicant]
US 10596380B2 · Levin et al. · 2020 [cited by applicant]
US 10610689B2 · Mika et al. · 2020 [cited by applicant]
US 10835751B2 · Stahmann et al. · 2020 [cited by applicant]
US 10967188B2 · Mika et al. · 2021 [cited by applicant]
US 11083894B2 · Levin et al. · 2021 [cited by applicant]
US 11097108B2 · Mika et al. · 2021 [cited by applicant]
US 11389658B2 · Mika et al. · 2022 [cited by applicant]
US 11426589B2 · Mika et al. · 2022 [cited by applicant]
US 11452875B2 · Mika et al. · 2022 [cited by applicant]
US 11529520B2 · Levin et al. · 2022 [cited by applicant]
US 11712567B2 · Mika et al. · 2023 [cited by applicant]
US 11759639B2 · Levin et al. · 2023 [cited by applicant]
US 11969598B2 · Mika et al. · 2024 [cited by applicant]
US 11986661B2 · Mika et al. · 2024 [cited by applicant]
US 12208271B2 · Mika et al. · 2025 [cited by applicant]
US 12239839B2 · Levin et al. · 2025 [cited by applicant]
US 12246180B2 · Mika et al. · 2025 [cited by applicant]
US 20010031993A1 · Salo et al. · 2001 [cited by applicant]
US 20040044361A1 · Frazier et al. · 2004 [cited by applicant]
US 20040049235A1 · Deno et al. · 2004 [cited by applicant]
US 20040138715A1 · van Groeningen et al. · 2004 [cited by applicant]
US 20040186523A1 · Florio · 2004 [cited by applicant]
US 20040199210A1 · Shelchuk · 2004 [cited by applicant]
US 20040215268A1 · Corbucci · 2004 [cited by applicant]
US 20050038478A1 · Klepfer et al. · 2005 [cited by applicant]
US 20050070952A1 · Devellian · 2005 [cited by applicant]
US 20050075676A1 · Deno et al. · 2005 [cited by applicant]
US 20050090872A1 · Deno et al. · 2005 [cited by applicant]
US 20050101998A1 · Kleckner et al. · 2005 [cited by applicant]
US 20050143785A1 · Libbus · 2005 [cited by applicant]
US 20050149128A1 · Heil et al. · 2005 [cited by applicant]
US 20050149131A1 · Libbus et al. · 2005 [cited by applicant]
US 20050149143A1 · Libbus et al. · 2005 [cited by applicant]
US 20050165454A1 · Chinchoy · 2005 [cited by applicant]
US 20050234543A1 · Glaser et al. · 2005 [cited by applicant]
US 20060041283A1 · Gelfand et al. · 2006 [cited by applicant]
US 20060173502A1 · Baynham · 2006 [cited by applicant]
US 20060264980A1 · Khairkhahan et al. · 2006 [cited by applicant]
US 20070073352A1 · Euler et al. · 2007 [cited by applicant]
US 20070239037A1 · Ghio et al. · 2007 [cited by applicant]
US 20070299475A1 · Levin et al. · 2007 [cited by applicant]
US 20070299477A1 · Kleckner et al. · 2007 [cited by applicant]
US 20080027488A1 · Coles et al. · 2008 [cited by applicant]
US 20080077187A1 · Levin et al. · 2008 [cited by applicant]
US 20080109043A1 · Salo et al. · 2008 [cited by applicant]
US 20080154322A1 · Jackson et al. · 2008 [cited by applicant]
US 20080275531A1 · Bulkes et al. · 2008 [cited by applicant]
US 20080281368A1 · Bulkes et al. · 2008 [cited by applicant]
US 20090018608A1 · Schwartz et al. · 2009 [cited by applicant]
US 20090036940A1 · Wei et al. · 2009 [cited by applicant]
US 20090118783A1 · Patangay et al. · 2009 [cited by applicant]
US 20090143838A1 · Libbus et al. · 2009 [cited by applicant]
US 20090247809A1 · Loeb et al. · 2009 [cited by applicant]
US 20100094370A1 · Levin et al. · 2010 [cited by applicant]
US 20100204741A1 · Tweden et al. · 2010 [cited by applicant]
US 20100312301A1 · Stahmann · 2010 [cited by applicant]
US 20110160787A1 · Greenhut et al. · 2011 [cited by applicant]
US 20110172731A1 · Levin et al. · 2011 [cited by applicant]
US 20110224749A1 · Ben-David et al. · 2011 [cited by applicant]
US 20120109237A1 · Xiao et al. · 2012 [cited by applicant]
US 20120158082A1 · Katra · 2012 [cited by applicant]
US 20120215272A1 · Levin et al. · 2012 [cited by applicant]
US 20120215275A1 · Wenzel et al. · 2012 [cited by applicant]
US 20140128934A1 · Schwartz et al. · 2014 [cited by applicant]
US 20140180353A1 · Mika et al. · 2014 [cited by applicant]
US 20140214115A1 · Greiner et al. · 2014 [cited by applicant]
US 20150051660A1 · Meyer · 2015 [cited by applicant]
US 20150094784A1 · Karst et al. · 2015 [cited by applicant]
US 20150258342A1 · Mika et al. · 2015 [cited by applicant]
US 20160129084A1 · Caggiano et al. · 2016 [cited by applicant]
US 20160243368A1 · Mika et al. · 2016 [cited by applicant]
US 20160263383A1 · Levin et al. · 2016 [cited by applicant]
US 20160339244A1 · Levin et al. · 2016 [cited by applicant]
US 20170072203A1 · Mika et al. · 2017 [cited by applicant]
US 20170080235A1 · Mika et al. · 2017 [cited by applicant]
US 20170239481A1 · Mika et al. · 2017 [cited by applicant]
US 20170291032A1 · Levin et al. · 2017 [cited by applicant]
US 20170304048A1 · Mika et al. · 2017 [cited by applicant]
US 20180185652A1 · Mika et al. · 2018 [cited by applicant]
US 20180256899A1 · Mika et al. · 2018 [cited by applicant]
US 20190001141A1 · Mika et al. · 2019 [cited by applicant]
US 20190269927A1 · Mika et al. · 2019 [cited by applicant]
US 20190275336A1 · Levin et al. · 2019 [cited by applicant]
US 20190351237A1 · Mika et al. · 2019 [cited by applicant]
US 20200094060A1 · Mika et al. · 2020 [cited by applicant]
US 20200121451A1 · Mika et al. · 2020 [cited by applicant]
US 20200254252A1 · Levin et al. · 2020 [cited by applicant]
US 20200346015A1 · Harkema et al. · 2020 [cited by applicant]
US 20210346702A1 · Mika et al. · 2021 [cited by applicant]
US 20220008725A1 · Levin et al. · 2022 [cited by applicant]
US 20230026613A1 · Mika et al. · 2023 [cited by applicant]
US 20230032051A1 · Mika et al. · 2023 [cited by applicant]
US 20230158308A1 · Levin et al. · 2023 [cited by applicant]
US 20230405336A1 · Mika et al. · 2023 [cited by applicant]
US 20240033517A1 · Levin et al. · 2024 [cited by applicant]
US 20240173553A1 · Mika et al. · 2024 [cited by applicant]
US 20240299752A1 · Mika et al. · 2024 [cited by applicant]
US 20240335668A1 · Mika et al. · 2024 [cited by applicant]
US 20250152941A1 · Levin et al. · 2025 [cited by applicant]
US 20250152945A1 · Mika et al. · 2025 [cited by applicant]
AU 2013361318 · 2018 [cited by applicant]
AU 2014367229B2 · 2019 [cited by applicant]
AU 2016319787 · 2021 [cited by applicant]
AU 2019204758 · 2021 [cited by applicant]
CA 2933278A1 · 2015 [cited by applicant]
CA 2933278C · 2023 [cited by applicant]
CA 2996312C · 2024 [cited by applicant]
CN 1446592A · 2003 [cited by applicant]
CN 1662278A · 2005 [cited by applicant]
CN 2897151Y · 2007 [cited by applicant]
CN 101309722A · 2008 [cited by applicant]
CN 101980657A · 2011 [cited by applicant]
CN 102159279A · 2011 [cited by applicant]
CN 102300603A · 2011 [cited by applicant]
CN 102551878A · 2012 [cited by applicant]
CN 103338709A · 2013 [cited by applicant]
CN 106029165A · 2016 [cited by applicant]
CN 104968392B · 2017 [cited by applicant]
CN 107715299A · 2018 [cited by applicant]
CN 108025173A · 2018 [cited by applicant]
CN 106029165B · 2018 [cited by applicant]
CN 109219465 · 2019 [cited by applicant]
CN 109364374A · 2019 [cited by applicant]
CN 107715299B · 2021 [cited by applicant]
CN 108025173B · 2022 [cited by applicant]
CN 109364374B · 2022 [cited by applicant]
CN 109219465B · 2023 [cited by applicant]
CN 117282025A · 2023 [cited by applicant]
EP 0532148 · 1993 [cited by applicant]
EP 2241348 · 2010 [cited by applicant]
EP 2374503A1 · 2011 [cited by applicant]
EP 2934669B1 · 2017 [cited by applicant]
EP 3238777A2 · 2017 [cited by applicant]
EP 3082949B1 · 2018 [cited by applicant]
EP 3461531A1 · 2019 [cited by applicant]
EP 3238777B1 · 2019 [cited by applicant]
EP 3639888A1 · 2020 [cited by applicant]
EP 3461531B1 · 2020 [cited by applicant]
EP 3639888B1 · 2021 [cited by applicant]
EP 3347090B1 · 2021 [cited by applicant]
EP 3445443B1 · 2021 [cited by applicant]
EP 3954429A2 · 2022 [cited by applicant]
EP 3954429A3 · 2022 [cited by applicant]
EP 3954429B1 · 2023 [cited by applicant]
EP 4233800A2 · 2023 [cited by applicant]
HK 1226016B2 · 2019 [cited by applicant]
HK 1243968B · 2021 [cited by applicant]
IN 202148037573A · 2021 [cited by applicant]
IN 202248072569A · 2022 [cited by applicant]
JP H07171218A · 1995 [cited by applicant]
JP 2620819 · 1997 [cited by applicant]
JP 2002505172A · 2002 [cited by applicant]
JP 2007519441A · 2007 [cited by applicant]
JP 2007527742A · 2007 [cited by applicant]
JP 2007531609A · 2007 [cited by applicant]
JP 2010508979A · 2010 [cited by applicant]
JP 2010509024 · 2010 [cited by applicant]
JP 2010512958A · 2010 [cited by applicant]
JP 2010512855A · 2010 [cited by applicant]
JP 2010536481A · 2010 [cited by applicant]
JP 2010536530A · 2010 [cited by applicant]
JP 2016501639A · 2016 [cited by applicant]
JP 2016540589A · 2016 [cited by applicant]
JP 2018526135 · 2018 [cited by applicant]
JP 2019042579 · 2019 [cited by applicant]
JP 6510421B2 · 2019 [cited by applicant]
JP 2019517842 · 2019 [cited by applicant]
JP 2019111408 · 2019 [cited by applicant]
JP 6831087B2 · 2021 [cited by applicant]
JP 2021013822A · 2021 [cited by applicant]
JP 6839163B2 · 2021 [cited by applicant]
JP 6999545 · 2021 [cited by applicant]
JP 7050693B2 · 2022 [cited by applicant]
JP 2022087144A · 2022 [cited by applicant]
JP 7138202B2 · 2022 [cited by applicant]
JP 2022169807A · 2022 [cited by applicant]
JP 7222962B2 · 2023 [cited by applicant]
JP 7395638B2 · 2023 [cited by applicant]
JP 2024037754A · 2024 [cited by applicant]
JP 7672471B2 · 2025 [cited by applicant]
JP 2025108698A · 2025 [cited by applicant]
KR 102221586B1 · 2021 [cited by applicant]
KR 102323562B1 · 2021 [cited by applicant]
KR 102367191B1 · 2022 [cited by applicant]
KR 102471841B1 · 2022 [cited by applicant]
KR 102471841B2 · 2022 [cited by applicant]
KR 102630590B1 · 2024 [cited by applicant]
WO 9944680A1 · 1999 [cited by applicant]
WO 2009035515A1 · 2005 [cited by applicant]
WO 2005063332A1 · 2005 [cited by applicant]
WO 2005097256A2 · 2005 [cited by applicant]
WO 2007007058A1 · 2007 [cited by applicant]
WO 2007021258 · 2007 [cited by applicant]
WO 2007044279A1 · 2007 [cited by applicant]
WO 2008057631A1 · 2008 [cited by applicant]
WO 2008063470A1 · 2008 [cited by applicant]
WO 2008076853A2 · 2008 [cited by applicant]
WO 2008079370A1 · 2008 [cited by applicant]
WO 2014100429A1 · 2014 [cited by applicant]
WO 2015094401A1 · 2015 [cited by applicant]
WO 2017044794A1 · 2017 [cited by applicant]
WO 2017184912A2 · 2017 [cited by applicant]
WO 2023230501A2 · 2023 [cited by applicant]
WO 2023235722A1 · 2023 [cited by applicant]
Response to Office Action dated Feb. 9, 2023 in Canadian Patent Application No. 2996312. [cited by applicant]
Notice of Intention to Grant dated Feb. 21, 2023 in European Patent Application No. 21201099.5. [cited by applicant]
Response to Office Action dated Mar. 3, 2023 in Chinese Patent Application No. 201780034227X, and English Translation thereof. [cited by applicant]
First Examination Report dated Mar. 10, 2023 in Indian Patent Application No. 202248072569. [cited by applicant]
Office Action dated Mar. 6, 2023 in Canadian Patent Application No. 3021336. [cited by applicant]
Office Action dated Mar. 30, 2023 in Japanese Patent Application No. 2022-054216, with English translation thereof. [cited by applicant]
Office Action dated Apr. 10, 2023 in Korean Patent Application No. 10-2018-7010005, and machine English translation thereof. [cited by applicant]
Decision to Grant mailed Mar. 3, 2022 in Japanese Patent Application No. JP2018-554557, and English translation thereof. [cited by applicant]
First Examination Report mailed Mar. 17, 2022 in Indian Patent Application No. 202148037573. [cited by applicant]
Extended European Search Report dated Apr. 7, 2022 in European Patent Application No. 21201099.5. [cited by applicant]
Hearing Notice mailed Apr. 26, 2022 in Indian Patent Application No. 4286/CHENP/2015. [cited by applicant]
Office Action mailed Mar. 3, 2022 in U.S. Appl. No. 16/794,478. [cited by applicant]
Notice of Allowance mailed Mar. 7, 2022 in U.S. Appl. No. 16/431,776. [cited by applicant]
Amendment filed Mar. 16, 2022 in U.S. Appl. No. 16/663,573. [cited by applicant]
Response to First Examination Report filed Apr. 6, 2022 in Indian Application No. 201847012769. [cited by applicant]
Response to Office Action filed Apr. 11, 2022 in Korean Patent Application No. 10-2021-7035610, and machine English translation thereof. [cited by applicant]
Response to Office Action filed Apr. 25, 2022 in Chinese Patent Application No. 2018113777986 and English translation thereof. [cited by applicant]
Notice of Allowance mailed Apr. 29, 2022 in U.S. Appl. No. 16/663,573. [cited by applicant]
Response to Second Examination Report filed May 4, 2022 in Australian Application No. 2017252310. [cited by applicant]
Notice of Allowance mailed May 6, 2022 in U.S. Appl. No. 16/583,371. [cited by applicant]
Third Examination Report dated Nov. 11, 2024 in Australian Patent Application No. 2022246435. [cited by applicant]
Final Office Action dated Nov. 14, 2024 in Japanese Patent Application No. 2022-140686 and machine English translation thereof. [cited by applicant]
Corrected Notice of Allowability dated Nov. 14, 2024 in U.S. Appl. No. 18/334,436. [cited by applicant]
Corrected Notice of Allowability dated Nov. 21, 2024 in U.S. Appl. No. 18/446,671. [cited by applicant]
Notice of Allowance mailed Dec. 4, 2024 in U.S. Appl. No. 18/545,095. [cited by applicant]
Response to Office Action filed Dec. 6, 2024 in Canadian Patent Application No. 3147251. [cited by applicant]
Response to Third Examination Report filed Dec. 6, 2024 in Australian Application No. 2022246435. [cited by applicant]
Notification Concerning Transmittal of International Preliminary Report On Patentability (IPRP) dated Dec. 5, 2024 in International Application No. PCT/US2023/067392. [cited by applicant]
Notification Concerning Transmittal of International Preliminary Report On Patentability (IPRP) dated Dec. 12, 2024 in International Application No. PCT/US2023/067649. [cited by applicant]
Notice of Acceptance dated Dec. 16, 2024 in Australian Patent Application No. 2022246435. [cited by applicant]
Office Action dated Dec. 18, 2024 in U.S. Appl. No. 18/057,877. [cited by applicant]
Corrected Notice of Allowability dated Dec. 27, 2024 in U.S. Appl. No. 18/334,436. [cited by applicant]
Corrected Notice of Allowability dated Feb. 3, 2025 in U.S. Appl. No. 18/446,671. [cited by applicant]
Office Action dated Oct. 19, 2022 in Chinese Patent Application No. 201780034227X, and English translation thereof. [cited by applicant]
Corrected Notice of Allowability dated Nov. 18, 2022 in U.S. Appl. No. 16/794,478. [cited by applicant]
Office Action mailed Nov. 22, 2022 in U.S. Appl. No. 17/205,114. [cited by applicant]
Notice of Decision to Grant a Patent dated Dec. 8, 2022 in Japanese Patent Application No. 2020-189356, and English translation thereof. [cited by applicant]
Response to First Examination Report filed Dec. 15, 2022 in Indian Patent Application No. 202148037573. [cited by applicant]
Response to First Examination Report filed Dec. 26, 2022 in Indian Patent Application No. 202248006588. [cited by applicant]
Office Action mailed Jan. 19, 2023 in U.S. Appl. No. 17/361,774. [cited by applicant]
Response to Final Office Action filed Aug. 8, 2022 in Japanese Patent Application No. 2020189356, with machine English translation thereof and English translation of claims. [cited by applicant]
Notice of Allowance mailed Aug. 17, 2022 in U.S. Appl. No. 16/794,478. [cited by applicant]
Notice of Allowability mailed Aug. 17, 2022 in U.S. Appl. No. 16/583,371. [cited by applicant]
Notice of Allowance mailed Aug. 29, 2022 in Korean Patent Application No. 10-2021-7035610, and machine English translation thereof. [cited by applicant]
Notice of Allowance dated Aug. 30, 2022 in Canadian Patent Application 2,933,278. [cited by applicant]
Office Action dated Oct. 11, 2022 in Canadian Patent Application No. 2,996,312. [cited by applicant]
Certificate of Grant dated Oct. 20, 2022 in Australian Patent Application No. 2017252310. [cited by applicant]
Intimation of Grant and Patent Certificate dated Oct. 26, 2022 in Indian Patent Application No. 201847042937. [cited by applicant]
Response to EPO Communication dated Oct. 27, 2022 in European Patent Application No. 21201099.5. [cited by applicant]
Office Action dated Feb. 4, 2020 in Canada Patent Application No. 2893222. [cited by applicant]
Extended European Search Report dated Mar. 25, 2020 in European Patent Application No. 19196148.1. [cited by applicant]
Notice of Intention to Grant dated Mar. 26, 2020 in European Patent Application No. 18205392.6. [cited by applicant]
Office Action dated Apr. 28, 2020 in European Patent Application No. 19196148.1. [cited by applicant]
Response to Office Action filed May 5, 2020 in Canada Patent Application No. 2893222. [cited by applicant]
Office Action dated May 7, 2020 in Japanese Patent No. 2019-072248, and English translation thereof. [cited by applicant]
Response to Office Action filed May 12, 2020 in Japanese Patent Application No. 2018-238255, and English translation thereof. [cited by applicant]
Office Action dated May 15, 2020 in Korean Patent No. 10-2015-7019640, and English translation thereof. [cited by applicant]
Office Action dated May 19, 2020 in Australian Patent No. 2016319787. [cited by applicant]
Response to Office Action filed Jun. 3, 2020 in European Patent Application No. 17786669.6. [cited by applicant]
Office Action dated Jun. 4, 2020 in European Patent Application No. 16845150.8. [cited by applicant]
Office Action mailed Jun. 8, 2020 in U.S. Appl. No. 16/359,218. [cited by applicant]
Response to Office Action filed Jun. 19, 2020 Japanese Patent No. 2019-072248, and English translation thereof. [cited by applicant]
Lopez et al., “Reducing Heart Rate of the Dog by Electrical Stimulation”, pp. 414-429, vol. 15 (Circ. Res. 1964). [cited by applicant]
Lister et al., “The Hemodynamic Effect of Slowing the Heart Rate by Paired or Coupled Stimulation of the Atria”, pp. 362-368 (Am. Heart J. Mar. 1967). [cited by applicant]
Braunwald et al., “Editorial: Paired Electrical Stimulation of the Heart: A Physiologic Riddle and a Clinical Challenge,” pp. 677-681, vol. 32, No. 5 (Circulation Nov. 1965). [cited by applicant]
Arbel et al., “Successful Treatment of Drug-Resistant Atrial Tachycardia and Intractable Congestive Heart Failure with Permanent Coupled Atrial Pacing,” pp. 336-340, vol. 41 (Am. J. or Cardiology Feb. 1978). [cited by applicant]
“Information Manual, Model 5837 R-Wave Coupled Pulse Generator”, 20 pages, Prelim. Ed. III, Medtronic (Jul. 1965). [cited by applicant]
Siddons et al., Cardiac Pacemakers, pp. 200-217, Pub. No. 680 of American Lecture Series (1968, Charles Thomas Publisher). [cited by applicant]
Schooderwoerd et al., “Atrial Natriuretic Peptides During Experimental Atrial Tachycardia: Role of Developing Tachycardiomyopathy,” pp. 927-932, vol. 15, No. 8 (J. of Cardiovascular Electrophysiology Aug. 2004). [cited by applicant]
Nishimura, Kazunobu et al., “Atrial pacing stimulates secretion of atrial natriuretic polypeptide without elevation of atrial pressure in awake dogs with experimental complete atrioventricular block.” Circ. Res. 1990;66… [cited by applicant]
Willems, Rik M.D. et al., “Different Patterns of Angiotensin II and Atrial Natriuretic Peptide Secretion in a Sheep Model of Atrial Fibrillation.” Journal of Cardiovascular Electrophysiology. 2001;12.12;1387-1392. [cited by applicant]
Zupan, Igor et al., “Effects of Systolic Atrial Function on Plasma Renin Activity and Natriuretic Peptide Secretion after High Rate Atrial and Ventricular Pacing in Dogs.” Pace. 2005;28.Supp 1;S270-S274. [cited by applicant]
Calderone, Angelino “The Therapeutic Effect of Natriuretic Peptides in Heart Failure; Differential Regulation of Endothelial and Inducible Nitric Oxide Synthases” Heart Failure Reviews, 2003;8;55-70. [cited by applicant]
Han, Bo et al., “Cardiovascular Effects of Natriuretic Peptides and Their Interrelation with Endothelin-1” Cardiovascular Drugs and Therapy, 2003;17;41-42. [cited by applicant]
PCT Invitation to Pay Additional Fees mailed Oct. 17, 2014 in International Application No. PCT/US2014/042777. [cited by applicant]
PCT Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority; International Search Report; and Written Opinion, mailed Jan. 2, 2015 in International… [cited by applicant]
PCT Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority; Declaration of Non-Establishment of International Search Report; and PCT Written Opini… [cited by applicant]
Notice of Allowance mailed Dec. 16, 2014 in U.S. Appl. No. 13/826,215. [cited by applicant]
Office Action mailed Jan. 29, 2015 in U.S. Appl. No. 13/688,978. [cited by applicant]
Office Action mailed Jun. 4, 2015 in U.S. Appl. No. 13/957,499. [cited by applicant]
Office Action mailed Jul. 13, 2015 in U.S. Appl. No. 14/642,952. [cited by applicant]
Office Action mailed Aug. 14, 2015 in U.S. Appl. No. 13/688,978. [cited by applicant]
Amendment filed Oct. 9, 2015 in U.S. Appl. No. 14/642,952. [cited by applicant]
Amendment filed Nov. 5, 2015 in U.S. Appl. No. 13/688,978. [cited by applicant]
Office Action mailed Nov. 4, 2015 in U.S. Appl. No. 14/427,478. [cited by applicant]
Amendment filed Nov. 30, 2015 in U.S. Appl. No. 13/957,499. [cited by applicant]
Notice of Allowance mailed Jan. 8, 2016 in U.S. Appl. No. 14/642,952. [cited by applicant]
Amendment filed Jan. 13, 2016 in U.S. Appl. No. 14/427,478. [cited by applicant]
Notice of Allowance mailed Feb. 12, 2016 in U.S. Appl. No. 13/688,978. [cited by applicant]
Notice of Allowance mailed Feb. 12, 2016 in U.S. Appl. No. 14/427,478. [cited by applicant]
Office Action mailed Mar. 4, 2016 in U.S. Appl. No. 14/667,931. [cited by applicant]
Notice of Allowance mailed Apr. 13, 2016 in U.S. Appl. No. 13/957,499. [cited by applicant]
Office Action issued May 27, 2016 in European Patent Application No. 13826807.3. [cited by applicant]
Office Action mailed Jun. 28, 2016 in U.S. Appl. No. 15/143,742. [cited by applicant]
Amendment filed Jul. 25, 2016 in U.S. Appl. No. 14/667,931. [cited by applicant]
Office Action mailed Jul. 27, 2016 in U.S. Appl. No. 15/163,078. [cited by applicant]
Notice of Allowance issued Aug. 17, 2016 in U.S. Appl. No. 14/667,931. [cited by applicant]
Amendment filed Sep. 27, 2016 in U.S. Appl. No. 15/143,742. [cited by applicant]
Office Action issued Sep. 5, 2016 in Chinese Patent Application No. 201380072479.3, and English translation thereof. [cited by applicant]
Response to Office Action, filed Sep. 27, 2016 in European Patent Application No. 13826807.3. [cited by applicant]
Amendment Filed Oct. 26, 2016 in U.S. Appl. No. 15/163,078. [cited by applicant]
Notice of Allowance mailed Jan. 18, 2017 in U.S. Appl. No. 15/143,742. [cited by applicant]
PCT Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority; International Search Report; and Written Opinion, mailed Nov. 28, 2016 in Internationa… [cited by applicant]
Notice of Intention to Grant issued Jan. 3, 2017 in European Patent Application No. 13826807.3. [cited by applicant]
Response to Office Action, filed Jan. 19, 2017, in Chinese Patent Application No. 201380072479.3, and machine English translation thereof. [cited by applicant]
Notice of Allowance mailed Mar. 15, 2017 in U.S. Appl. No. 15/163,078. [cited by applicant]
Office Action mailed Mar. 24, 2017 in U.S. Appl. No. 15/372,603. [cited by applicant]
Decision to Grant issued May 26, 2017 in European Patent Application No. 13826807.3. [cited by applicant]
Office Action mailed Jun. 16, 2017 in U.S. Appl. No. 14/652,856. [cited by applicant]
Amendment filed Jun. 26, 2017 in U.S. Appl. No. 15/372,603. [cited by applicant]
Notice of Allowance dated Sep. 7, 2023 in Canadian Patent Application No. 2,996,312. [cited by applicant]
Office Action mailed Sep. 25, 2023 in U.S. Appl. No. 17/882,811. [cited by applicant]
Office Action dated Oct. 3, 2023 in Canadian Patent Application No. 3,147,251. [cited by applicant]
Decision to Grant a Patent dated Oct. 5, 2023 in Japanese Patent No. 2022-054216, and English translation thereof. [cited by applicant]
Extended European Search Report dated Oct. 6, 2023 in European Patent Application No. 23181110.0. [cited by applicant]
Notice of Allowance mailed Oct. 30, 2023 in Korean Patent Application No. 10-2018-7010005, and English machine translation thereof. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2023/067649, mailed on Nov. 6, 2023. [cited by applicant]
Response to Office Action filed Nov. 13, 2023 in Japanese Patent Application No. 2022-140686, with English Translation of Amended Claims and English Machine Translation of Remarks. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2023/067392, mailed on Nov. 16, 2023. [cited by applicant]
Response to Office Action filed Dec. 4, 2023 in U.S. Appl. No. 17/883,905. [cited by applicant]
Office Action dated May 22, 2024 in U.S. Appl. No. 18/446,671. [cited by applicant]
Response to First Examination Report dated May 31, 2024 in Australian Patent Application 2022246435. [cited by applicant]
Office Action dated Jun. 4, 2024 in U.S. Appl. No. 18/057,877. [cited by applicant]
Second Examination Report dated Jun. 20, 2024 in Australian Patent Application No. 2022246435. [cited by applicant]
Request for Reconsideration dated Jun. 28, 2024 in U.S. Appl. No. 18/545,095. [cited by applicant]
U.S. Appl. No. 18/610,418, filed Mar. 20, 2024. [cited by applicant]
U.S. Appl. No. 18/636,466, filed Apr. 16, 2024. [cited by applicant]
Office Action dated Jul. 22, 2024 in U.S. Appl. No. 18/545,095. [cited by applicant]
Amendment filed Jul. 23, 2024 in U.S. Appl. No. 18/334,436. [cited by applicant]
Response to Office Action dated Jul. 29, 2024 in Canadian Patent Application No. 3021336. [cited by applicant]
EPO Communication dated Jul. 31, 2024 in European Patent Application No. 23181110.0. [cited by applicant]
Office Action dated Aug. 5, 2024 in U.S. Appl. No. 18/545,095. [cited by applicant]
Office Action dated May 9, 2024 in Canadian Patent Application No. 3184556. [cited by applicant]
Cited By (1)
US 12,605,554